Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review.
European child & adolescent psychiatry 2025 Alisha M Bruton, Dalton G Wesemann, Taryn A Machingo et al. 20 citations
Mood disorders, anxiety, and suicidality in youth are increasing and rapid-acting treatments are urgently needed. One potential is ketamine or its enantiomer esketamine, which was FDA approved in 2019 to treat major depressive disorder with suicidality in adults. This systematic review evaluated the evidence for the clinical use of ketamine to treat mood disorders, anxiety, and suicidality in...